期刊文献+

特发性肺纤维化患者生存预后因素的回顾性分析 被引量:10

Retrospective analysis of the prognosis factors in patients with idiopathic pulmonary fibrosis
原文传递
导出
摘要 目的探讨临床指标、肺生理变化及BALF细胞分类对判断特发性肺纤维化(IPF)患者预后的价值,评估糖皮质激素或糖皮质激素联合细胞毒类药物治疗IPF患者的影响。方法65例IPF患者分别接受临床评估和血气分析、肺功能、胸部高分辨率CT、心脏超声及BALF检查,分析各项指标对判断IPF患者预后的意义。采用Cox比例风险回归评价各指标的死亡危险度,采用KaplamMeier检验进行组间生存率比较。结果在平均随访38个月内,IPF患者的总体生存率为43.1%,确诊后的中位生存期为39个月;体重指数、杵状指、ESR、氧合指数、SaO2、肺总量占预计值%、DLCO占预计值%、肺动脉压和BALF中的中性粒细胞百分率是IPF患者预后的影响因素,其死亡危险度为0.842~1.945,Wald值为3.782—12.963,均P〈0.05;体重指数、杵状指、ESR、氧合指数、肺总量占预计值%和DLCO占预计值%的组问生存率比较,差异均有统计学意义(Log—rank值为3.907—10.452,均P〈0.05);采用糖皮质激素治疗和糖皮质激素联合细胞毒类药物治疗的IPF患者与未采用上述药物治疗的IPF患者组间生存率比较,差异无统计学意义(Log—rank值为2.405,P〉0.05)。结论体重指数、杵状指、ESR、氧合指数、肺总量占预计值%和DLCO占预计值%对IPF患者的生存预后可能具有参考价值,糖皮质激素或糖皮质激素联合细胞毒类药物治疗不能改变IPF患者的预后。 Objective To investigate the prognostic implications of clinical and physiological variables, and the cellular classification of bronchoalveolar lavage fluid (BALF) in patients with idiopathic pulmonary fibrosis (IPF). The effect of treatment with glucocortieoids with or without cytotoxic drugs was also evaluated. Methods The significauces of clinical, arterial blood gas analysis, pulmonary function test, lung high-resolution computed tomography, echoeardiography and BALF in the prognosis of patients with IPF were assessed in 65 patients with IPF at diagnosis. Univariate Cox proportional-hazards regression analysis was used to evaluate the various parameters associated with hazard ratio. The survival rates of all groups were compared using the Kaplau-Meier method. Results In 38 months of average follow-up time, the survival rate of the patients was 43. 1%, and the median survival time was 39 months after diagnosis. Univariate Cox proportional-hazards regression analysis showed that body mass index, clubbing fingers, ESR, PaO2/FiO2 , SaO2 , TLC%, DLCO%, pulmonary arterial pressure and the percent of neutrophil in BALF were factors that affected the prognosis of the patients with IPF ( HR O. 842 - 1. 945, Wald 3.782 12. 963, P 〈0. 05). In the meanwhile, the patients were divided into 2 groups by the median of significant variables in univariate Cox proportional-hazards regression analysis (the cut off point value ), and the survival rate group comparison showed statistically significant difference in body mass index, clubbing fingers, ESR, TLC% as well as DLCO% ( Log-rank 3. 907 - 10. 452, P 〈 0. 05 ), while glucocorticoids with or without cytotoxic drugs for patients with IPF did not change the prognosis ( Log-rank 2. 405, P 〉 0. 05). Conclusions Body mass index, clubbing fingers, ESR, PaO2/FiO2, TLC%, and DLCO% maybe the factors affecting the prognosis of patients with IPF, while glucocorticoids with or without cytotoxic drugs did not change the course of IPF.
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2011年第3期174-178,共5页 Chinese Journal of Tuberculosis and Respiratory Diseases
关键词 肺纤维化 预后 危险性评估 Pulmonary fibrosis Prognosis Risk assessment
  • 相关文献

参考文献19

  • 1Tzilas V, Koti A, Papandrinopoulou D, et al. Prognostic factors in idiopathic puhnonary fibrosis. Am J Med Sci, 2009,338: 481-485.
  • 2Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med, 2005,142 ( 12 Pt 1 ) :963-967.
  • 3American Thoracic Society. Idiopathic pulmonary fibrosis : diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med, 2000, 161 (2 Pt 1 ) :646-664.
  • 4特发性肺(间质)纤维化诊断和治疗指南(草案)[J].中华结核和呼吸杂志,2002,25(7):387-389. 被引量:631
  • 5Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med, 2004, 351 : 1655-1665.
  • 6Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis : multiple causes and multiple mechanisms? Eur Respir J, 2007, 30:835-839.
  • 7Han MK, Murray S, Fell CD, et al. Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J, 2008,31:1183-1188.
  • 8Alhamad EH, Masood M, Shaik SA, et al. Clinical and functional outcomes in Middle Eastern patients with idiopathic pulmonary fibrosis. Clin Respir J, 2008,2:220-226.
  • 9Alakhras M, Decker PA, Nadrous HF, et al. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest, 2007, 131:1448-1453.
  • 10Mura M, Belmonte C, Fanti S, et al. Inflammatory activity is still present in the advanced stages of idiopathic pulmonary fibrosis.Respirology, 2005,10:609-614.

共引文献630

同被引文献110

  • 1贾留群,文富强.特发性肺纤维化的研究进展及其治疗[J].世界临床药物,2013,34(1):12-16. 被引量:8
  • 2于晓敏,刘新民.肺功能检测在间质性肺疾病中的作用[J].国外医学(呼吸系统分册),2005,25(5):369-371. 被引量:16
  • 3许梅,姚红梅,朱绍英,杨杰.慢性阻塞性肺疾病合并肺间质纤维化的肺功能分析[J].贵州医药,2010,34(11):1013-1014. 被引量:3
  • 4Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med,2011,183 :788-824.
  • 5Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med,2007,176:277-284.
  • 6Iwai K, Mori T, Yamada N, et al. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med, 1994,150:670-675.
  • 7Hanson D, Winterbauer RH, Kirtland SH, et al. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest, 1995,108:305-310.
  • 8Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest, 1997,111:51-57.
  • 9Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med, 1998,157 : 1063-1072.
  • 10Mapel DW, Hunt WC, Utton R, et al. Idiopathic pulmonary fibrosis : survival in population based and hospital based cohorts. Thorax, 1998,53:469-476.

引证文献10

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部